3-(4-氟苯基)-1H-吲唑-5-甲腈 | 395100-12-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-(4-氟苯基)-1H-吲唑-5-甲腈
• 英文名称: 3-(4-fluorophenyl)-1H-indazole-5-carbonitrile
• 英文别名: 3-(4-fluorophenyl)-1H-5-indazolecarbonitrile
• CAS: 395100-12-6
• 化学式: C₁₄H₈FN₃
• 分子量: 237.236
• InChiKey: DAAULCRCVHOEKN-UHFFFAOYSA-N

物化性质

• 沸点：
  477.1±30.0 °C(Predicted)
• 密度：
  1.38

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  52.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4-氟苯基)-1H-吲唑-5-甲腈 在 盐酸 作用下， 以 乙醇 为溶剂， 生成 3-(4-fluorophenyl)-1H-indazole-5-carboximidic acid ethyl ester hydrochloride
  参考文献：
  名称：

  Indazole compounds, compositions thereof and methods of treatment therewith

  摘要：

  这项发明通常涉及使用吲唑化合物来治疗或预防与蛋白激酶相关的疾病，包括酪氨酸激酶，诸如增殖性疾病、炎症性疾病、异常血管生成及其相关疾病、动脉硬化、黄斑变性、糖尿病、肥胖、疼痛等。这些方法包括向有需要的患者施用有效量的吲唑化合物，以抑制、调节或控制酪氨酸激酶信号转导。本文中提供了一种新型的吲唑化合物或其药用可接受的盐。

  公开号：

  US20050009876A1
• 作为产物：
  描述：

  4-氟-3-(4-氟苯甲酰基)苯腈 在 一水合肼 、 肼 作用下， 以 水 为溶剂， 生成 3-(4-氟苯基)-1H-吲唑-5-甲腈
  参考文献：
  名称：

  Indazole compounds, compositions thereof and methods of treatment therewith

  摘要：

  这项发明通常涉及使用吲唑化合物来治疗或预防与蛋白激酶相关的疾病，包括酪氨酸激酶，诸如增殖性疾病、炎症性疾病、异常血管生成及其相关疾病、动脉硬化、黄斑变性、糖尿病、肥胖、疼痛等。这些方法包括向有需要的患者施用有效量的吲唑化合物，以抑制、调节或控制酪氨酸激酶信号转导。本文中提供了一种新型的吲唑化合物或其药用可接受的盐。

  公开号：

  US20050009876A1

文献信息

• Methods for treating an inflammatory condition or inhibiting JNK
  申请人：——

  公开号：US20040127536A1

  公开（公告）日：2004-07-01

  This invention is generally directed to Indazole Derivatives having the following structure: 1 or pharmaceutically acceptable salt thereof, wherein R 1 , R 2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of diseases and disorders that are responsive to JNK inhibition, such as an inflammatory disease or disorder. Thus, methods of treating such diseases and disorders are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

  这项发明通常涉及吲唑衍生物，具有以下结构： 1 或药用可接受的盐，其中R 1 ，R 2 和A如本文所述定义。这类化合物在治疗对JNK抑制剂有响应的广泛疾病和障碍，如炎症性疾病或障碍中具有用途。因此，还披露了治疗这些疾病和障碍的方法，以及包含一个或多个上述化合物的药物组合物。
• Indazole derivatives as JNK inhibitors and compositions and methods related thereto
  申请人：——

  公开号：US20020103229A1

  公开（公告）日：2002-08-01

  Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: 1 wherein R 1 , R 2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

  本发明公开了作为JNK选择性抑制剂的化合物。本发明的化合物是吲唑衍生物，具有以下结构： 1 其中R 1 ，R 2 和A如本文所述定义。此类化合物在治疗对JNK抑制产生响应的广泛病症方面具有用途。因此，还公开了治疗此类病症的方法，以及包含一个或多个上述化合物的药物组合物。
• Novel 1H-indazole compounds
  申请人：Oinuma Hitoshi

  公开号：US20050282880A1

  公开（公告）日：2005-12-22

  The present invention provides a novel 1H-indazole compound having an excellent JNK inhibitory action. More specifically, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein R 1 is a C 6 -C 14 aromatic cyclic hydrocarbon group etc.; R 2 , R 4 and R 5 each independently represent a hydrogen atom, a halogen atom, a cyano group etc.; L is a single bond, or a C 1 -C 6 alkylene group etc.; X is a single bond, or a group represented by —CO—NH— or —NH—CO—, etc.; and Y is a C 3 -C 8 cycloalkyl group, a C 6 -C 14 aromatic cyclic hydrocarbon group or a 5- to 14-membered aromatic heterocyclic group etc.

  本发明提供了一种新型的1H-吲唑化合物，具有出色的JNK抑制作用。更具体地说，提供了以下公式所表示的化合物，其盐或水合物。其中，R1是C6-C14芳香环烃基等；R2、R4和R5各自独立地表示氢原子、卤原子、氰基等；L是单键或C1-C6烷基等；X是单键或由—CO—NH—或—NH—CO—等表示的基团；Y是C3-C8环烷基、C6-C14芳香环烃基或5-至14成员芳香杂环基等。
• Novel 1h-indazole compound
  申请人：——

  公开号：US20040127538A1

  公开（公告）日：2004-07-01

  The present invention provides a novel 1H-indazole compound having an excellent JNK inhibitory action. More specifically, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. 1 Wherein R 1 is a C 6 -C 14 aromatic cyclic hydrocarbon group etc.; R 2 , R 4 and R 5 each independently represent a hydrogen atom, a halogen atom, a cyano group etc.; L is a single bond, or a C 1 -C 6 alkylene group etc.; X is a single bond, or a group represented by —CO—NH— or —NH—CO—, etc.; and Y is a C 3 -C 8 cycloalkyl group, a C 6 -C 14 aromatic cyclic hydrocarbon group or a 5- to 14-membered aromatic heterocyclic group etc.

  本发明提供了一种具有出色的JNK抑制作用的新型1H-吲唑化合物。更具体地，它提供了以下式子所表示的化合物、其盐或水合物。其中，R1为C6-C14芳香环烃基等；R2、R4和R5各自独立地表示氢原子、卤素原子、氰基等；L为单键或C1-C6烷基等；X为单键或由—CO—NH—或—NH—CO—等表示的基团；Y为C3-C8环烷基、C6-C14芳香环烃基或5-至14-环芳杂环基等。
• Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
  申请人：Signal Pharmaceuticals, LLC

  公开号：US07208513B2

  公开（公告）日：2007-04-24

  Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

  本发明揭示了具有选择性抑制JNK活性的化合物。本发明的化合物是具有以下结构的吲唑衍生物：其中R1、R2和A的定义如本文所述。这些化合物在治疗对JNK抑制有反应的广泛疾病方面具有用途。因此，本发明还揭示了治疗这些疾病的方法，以及包含上述化合物中的一个或多个化合物的制药组合物。